PERBEDAAN KADAR INTERLEUKIN-6 PADA PENDERITA HEPATITIS KRONIS DAN KARSINOMA HEPATOSELULER
| Main Authors: | , ELLIPTA HAPSARI, , dr. Neneng Ratnasari, SpPD-KGEH. |
|---|---|
| Format: | Thesis NonPeerReviewed |
| Terbitan: |
[Yogyakarta] : Universitas Gadjah Mada
, 2013
|
| Subjects: | |
| Online Access: |
https://repository.ugm.ac.id/126045/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=66235 |
Daftar Isi:
- Background. Interleukin-6 (IL-6) is a cytokine that plays a major role in the liver response to infection or systemic inflammation. Serum IL-6 increased in patients with chronic liver inflammation including hepatitis B, hepatitis C and steatohepatitis. Serum IL-6 is also increased in patients hepatocellulare carcinoma (HCC). Patients with chronic hepatitis B and chronic hepatitis C with high levels of IL-6 will develop into HCC. High levels of IL-6 would lead to the development of HCC in patients with hepatitis, so that IL-6 can be considered as a biological marker for HCC. Aim. This study aims to determine the elevated levels of interleukin-6 in patients with HCC compared with patients with chronic hepatitis. Method. The study design was cross-sectional study. Subjects were patients with chronic hepatitis B, chronic hepatitis C and HCC were treated in the clinic or hospitalized in the Internal Medicine ward Dr. Sardjito hospital that meet the inclusion and exclusion criterias. The variables studied were interleukin-6 as an outcome of chronic hepatitis and HCC. Results. There were 36 patients, consisting of 18 chronic hepatitis patients and 18 HCC patients, with with a mean of IL-6 in chronic hepatitis patients was 17.19 ± 2.59 pg/ml, while the mean of IL-6 in HCC patients was 90.42 ± 2.68 pg/ml. The mean levels of IL-6 in HCC patients was significantly higher than in chronic hepatitis patients statistically.